Edition:
United Kingdom

Corvus Pharmaceuticals Inc (CRVS.OQ)

CRVS.OQ on NASDAQ Stock Exchange Global Market

9.97USD
24 Apr 2018
Change (% chg)

$-0.41 (-3.95%)
Prev Close
$10.38
Open
$10.50
Day's High
$10.50
Day's Low
$9.95
Volume
23,897
Avg. Vol
40,474
52-wk High
$17.54
52-wk Low
$7.45

Chart for

About

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-onc... (more)

Overall

Beta: --
Market Cap(Mil.): $348.98
Shares Outstanding(Mil.): 20.93
Dividend: --
Yield (%): --

Financials

  CRVS.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -2.58 -- --
ROI: -40.42 1.58 14.38
ROE: -40.82 2.41 16.07

BRIEF-Adams Street Partners Reports 15.5 Pct Stake In Corvus Pharma

* ADAMS STREET PARTNERS, LLC REPORTS 15.5 PERCENT STAKE IN CORVUS PHARMACEUTICALS INC AS OF MARCH 12, 2018 - SEC FILING‍​

21 Mar 2018

BRIEF-BVF Partners Reports 6.7 Pct Passive Stake In Corvus Pharmaceuticals

* BVF PARTNERS L.P. REPORTS 6.7 PERCENT PASSIVE STAKE IN CORVUS PHARMACEUTICALS INC AS OF MARCH 8, 2018 - SEC FILING‍​ Source text: (http://bit.ly/2G67UVx) Further company coverage:

19 Mar 2018

BRIEF-Corvus Pharma Announces Pricing Of Public Offering Of Common Stock

* CORVUS PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

08 Mar 2018

BRIEF-Corvus Pharma Announces Proposed Public Offering Of Common Stock

* CORVUS PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

07 Mar 2018

BRIEF-Corvus Pharmaceuticals Qtrly Net Loss Per Share $0.58

* CORVUS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

01 Mar 2018

BRIEF-Corvus Pharmaceuticals reports third quarter 2017 financial results

* Corvus Pharmaceuticals reports third quarter 2017 financial results and clinical program update

02 Nov 2017

Earnings vs. Estimates